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Abstract
Objective
To describe a possible association between Graves’ disease
and nephrotic syndrome secondary to minimal change re-
nal disease and to review the literature related to renal
diseases in patients with Graves’ disease.
Methods
The clinical, laboratory, and renal biopsy findings in a
patient with Graves’ disease and minimal change renal
disease are discussed. In addition, the pertinent English-
language literature published from 1966 to 2009, deter-
mined by means of a MEDLINE search, is reviewed.
Results
A 63-year-old man who was admitted to the hospital with
nephrotic syndrome. Patient had a history of Graves’ dis-
ease for last 2 years with associated ophthalmopathy. He
had been treated with methimazole and low low-dose ste-
roids (prednisone 5 mg daily). Examination revealed gener-
alized oedemaedema and exophthalmoses. Laboratory tests
showed 6.62 g/day of proteinuria. Antinuclear antibodies,
anti-glomerular basement membrane antibodies, antineutro-
phil cytoplasmic antibody (ANCA), serum complement lev-
els, cryoglobulin, hepatitis screen and serum and urine
protein electrophoreses were normal. A kidney biopsy re-
vealed features consistent with minimal change disease on
light, immunofluorescence, and electron microscopy. The
patient had an excellent clinical and laboratory response
after treatment with steroids and near total thyroidectomy.
Conclusions
To the best of our knowledge, this is the fourth report of the
occurrence of minimal change disease in a patient with
Graves’ disease in the absence of any other immunologic
disorder known to be associated with minimal change renal
disease.
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Introduction
There have been several cases of thyroid diseases asso-
ciated with glomerular diseases [1–6]. Published studies,
however, have described only a few cases of the associ-
ation of Graves’ disease with primary renal diseases. We
describe a patient with Graves’ disease who had neph-
rotic syndrome due to minimal change disease (MCD)
and discuss the potential pathogenic mechanisms in-
volved in the renal lesions associated with autoimmune
thyroid disease.
Case report
A 63-year-old Caucasian man with a past medical history
of hypertension and Graves’ disease was initially admitted
to another hospital for a 30-pound weight gain, lower ex-
tremity edema and shortness of breath. There, he was trea-
ted for congestive heart failure with intravenous
furosemide. His creatinine increased from a baseline of
1.1 mg/dL (97.2 lmol/L) to 1.7 mg/dL (150.2 lmol/L).
Further workup revealed 7 g/day of proteinuria. The patient
was transferred to our hospital for further evaluation and
treatment. He was diagnosed with Graves’ disease 2 years
prior to admission when he experienced a 50-pound weight
loss, weakness and fatigue. He was also noted to have
exophthalmose, which was treated with radiation therapy.
He has been on varying doses of methimazole for the last 2
years and on a dose of 5 mg daily for the last 8 months. His
mother also had Graves’ disease, and his father was dia-
betic. The patient himself had no history of diabetes, and
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his glycosylated hemoglobin A1c was 5.9%. He denied any
prolonged use of nonsteroidal anti-inflammatory drugs.
Physical examination revealed an obese man with a
blood pressure of 170/88 mmHg, a pulse rate of 52 beats/
min and regular cardiac rhythm. Pertinent findings on sys-
temic examination were right eye exophthalmose, lower
extremity edema and clear lungs. The thyroid gland was
not enlarged. No bruit was detected over the thyroid gland.
Laboratory evaluation revealed mildly elevated thyroid stim-
ulating hormone of 5.59 mIU/L (normal, 3.5–5.5 mIU/L),
normal free thyroxine (T4) of 1.01 ng/dL (12.99 pmol/L) (nor-
mal, 0.80–1.80 ng/dL) and a normal free triiodothyronine
(T3) of 264 pg/dL (4.06 pmol/L) (normal, 230–420 pg/dL).
Results of additional tests showed a mild normochromic,
normocytic anemia; albumin 2.4 g/dL (24 g/L); normal lipid
profile (on a statin) and creatinine 1.7 mg/dL (150.2 lmol/L).
Urinalysis showed only one red blood cell (RBC)/high
power field and no casts. Spot urine protein-to-creatinine
ratio was 6.62 g/day. His chest X-ray was normal and echo-
cardiogram showed a left ventricular ejection fraction of
60%. Antinuclear antibodies, cryoglobulin, anti-streptolysin
O, anti-glomerular basement membrane, serum complement
(C3) level, hepatitis and antineutrophil cytoplasmic autoanti-
body (ANCA) screen were normal. Spun urine sediment was
significant for dysmorphic RBCs, occasional hyaline casts
containing RBCs and white blood cells and renal tubular
epithelial cells.
A kidney biopsy was performed. Light microscopy re-
vealed 12 glomeruli, none of which were globally or seg-
mentally sclerotic. Glomeruli showed up to mild mesangial
proliferation, with occasional foci of increased cells within
capillary lumens (Figure 1). No endocapillary foam cells or
podocyte hyperplasia/capping were noted. Some tubules
showed focal acute injury but there were only minimal
chronic changes in the vasculature and tubulointerstitium.
Immunofluorescence microscopy (10 glomeruli present)
showed no immunopositivity. Electron microscopy of
two glomeruli confirmed the above findings and revealed
near total podocyte foot process effacement with associated
microvillous transformation (Figure 2). While occasional
small electron-dense deposits were identified in the mesan-
gium, no subepithelial or subendothelial deposits were
seen. Endocapillary cellularity was somewhat increased,
associated with swollen endothelial cells (pathologist
thinks this could be an artifact). A minute focus of podo-
cyte stripping with reparative changes of the basement
membrane and a possible adhesion was present. However,
no unequivocal changes of segmental sclerosis were seen.
The findings were therefore felt to be consistent with MCD.
The patient was started on prednisone (1 mg/kg) but
heavy proteinuria persisted (11 g/day) despite being on
steroids for 2 weeks. Three weeks after the presentation,
the patient underwent near total thyroidectomy and repeat
laboratory work 2 weeks later showed a significant reduc-
tion in proteinuria (0.44 g/day). His creatinine also im-
proved to 1.0 mg/dL (88.4 lmol/L). Methimazole was
stopped. The patient remained on prednisone for 6 months
with resolution of edema, nephrotic range proteinuria and
atypia of the urine sediment. The clinical course and re-
sponse to treatment was felt to confirm the diagnosis of
MCD.
Discussion
Autoimmune thyroid diseases are occasionally associated
with glomerular diseases. A few case reports have been
published in the medical literature, as determined by a
MEDLINE search of English-language publications for
the interval from 1966 to 2010. Glomerular disease in as-
sociation with Graves’ disease may be attributable to an
unknown cause or to the use of antithyroid drugs or radio-
active iodine treatment. Membranous glomerulonephritis is
the most commonly reported renal disease in patients with
Graves’ disease [3] but over the last decade, there have
been a few case reports of Graves’ disease associated with
MCD. In 2002, Tanwani et al. [7] reported a case of the
concomitant occurrence of Graves’ disease and MCD. In
Fig. 1. Light microscopy revealed mild mesangial prominence and focal
increase in endolumenal cells. No global or segmental glomerulosclerosis
was noted. A proximal tubule (center, bottom) shows mild acute injury
(PAS reaction, original magnification 340).
Fig. 2. Ultrastructural studies revealed widespread acute podocyte injury,
with near total foot process effacement as well as microvillous transfor-
mation and condensation of the actin cytoskeleton. Some proteinaceous
material is noted in the capillary lumen (electron microscopy, original
magnification 38000).
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the same year, Holt et al. [8] reported the case of a patient in
whom Graves’ disease and MCD were diagnosed simulta-
neously and in whom relapse of the Graves’ disease was
invariably accompanied by relapse of MCD. More recently,
Esteve et al. [9] reported the case of a patient who was
diagnosed with Graves’ disease and was started on methi-
mazole therapy. She subsequently developed MCD, which
the authors attributed to hypothyroidism caused by antithy-
roid therapy.
MCD has been reported in association with other auto-
immune diseases, including other autoimmune thyroid dis-
eases. In 1996, Mundlein et al. [6] reported a case of
Graves’ disease, sarcoidosis and MCD. The patient was
diagnosed with MCD in 1984 and had a relapse in 1994.
Graves’ disease and sarcoidosis were diagnosed in April
1995. In 1996, the patient had concurrent relapses of
minimal change nephropathy and Graves’ disease [10].
Nishimoto et al. [11] reported a case of concomitant occur-
rence of minimal change nephropathy, sarcoidosis and Ha-
shimoto’s thyroiditis. A case report of IgA nephropathy,
sarcoidosis and chronic thyroiditis has also been described
in the literature [12]. At the same time, glomerular disease
has been reported to occur in association with sarcoidosis in
the absence of autoimmune thyroid disease [13, 14]. In our
patient, no clinical or radiologic evidence of sarcoidosis
was observed. Methimazole has been reported to be asso-
ciated with MCD [15] but our patient was on methimazole
for 2 years before he developed MCD. The literature also
suggests a high frequency of occurrence of ANCA positiv-
ity in propylthiouracil and methimazole-treated patients
with Graves’ disease. In our patient, ANCA screen was
negative.
The mechanism involved in the pathogenesis of MCD in
association with Graves’ disease is unclear. Some investi-
gators have suggested, however, that MCD may be a dis-
order of cell-mediated immunity. T lymphocytes secrete
various cytokines that may damage the glomerular epithe-
lial cells and increase the permeability of proteins [16, 17].
In addition, several studies suggest that cytokines have an
important role in the evolution of autoimmune thyroid dis-
eases, such as Hashimoto’s thyroiditis and Graves’ disease
[18]. Thus, concomitant occurrence of MCD in association
with autoimmune thyroid disease suggests an abnormality
of the immune system common to both disorders.
Conclusion
To our knowledge, this is the fourth case report of the
concomitant occurrence of Graves’ disease and minimal
change nephropathy in the absence of any other immuno-
logic condition known to occur in association with minimal
change nephropathy. In addition, this case report provides
further evidence that the two diseases may be linked to each
other by some unknown immune mechanism, as suggested
by Mundlein et al. [6]. Patients with concurrent autoim-
mune thyroid disease and nephrotic syndrome should
undergo renal biopsy, inasmuch as the treatment and
prognosis varies for each histologic entity. Documentation
and investigation of such cases may provide further in-
sights into the immunopathogenesis of minimal change
glomerulonephritis.
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